Baropharm set for Kosdaq debut on Nov. 11

Résumé détaillé

Baropharm, a South Korean digital platform serving pharmacies, is set to list on the Kosdaq market on Nov. 11 as it expands beyond pharmaceutical ordering services into cosmetics,…

Baropharm, a South Korean digital platform serving pharmacies, is set to list on the Kosdaq market on Nov. 11 as it expands beyond pharmaceutical ordering services into cosmetics, drug manufacturing and overseas markets.

Founded in November 2019, Baropharm operates an integrated ordering platform that allows pharmacies to compare drug inventories and prices across multiple wholesalers and place orders through a single interface.

The service replaces a fragmented purchasing process in which pharmacists previously had to access individual wholesalers’ systems to check product availability and pricing.

Baropharm has attracted more than 90 percent of South Korea’s pharmacies to its platform. As of June, 16,357 pharmacies were active monthly users.

The total value of pharmacy orders processed through its platform reached 2.02 trillion won ($1.5 billion) last year, while transactions on its Baropharm Mall marketplace totaled 341.7 billion won.

Building on its pharmaceutical ordering and brokerage business, the company has diversified into private-label products, drug manufacturing and distribution.

As skincare products containing functional ingredients gain popularity, more consumers are visiting pharmacies for professional advice on product formulations and ingredients.

Baropharm has responded by developing partnerships with pharmaceutical and beauty companies, purchasing their products directly and supplying them to pharmacies.

Revenue from the partnership business increased from 23.2 billion won in 2024 to 69.6 billion won in 2025 and is projected to reach 127.5 billion won this year, according to the company.

Début de l'article, extrait de Pulse (Maeil Business). Pour lire la suite, ouvrez l'article chez le média.